| (Values in U.S. Thousands) | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 |
| Sales | 38,710 | 38,520 | 10,610 | 16,100 | 18,570 |
| Sales Growth | +0.49% | +263.05% | -34.10% | -13.30% | +137.16% |
| Net Income | -29,070 | -28,710 | -60,810 | -81,390 | -69,800 |
| Net Income Growth | -1.25% | +52.79% | +25.29% | -16.60% | +21.14% |
Bluebird Bio Inc (BLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.'The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent '-thalassemia (TDT).
Fiscal Year End Date: 12/31